当前位置: X-MOL 学术Lancet HIV › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study
The Lancet HIV ( IF 12.8 ) Pub Date : 2024-10-28 , DOI: 10.1016/s2352-3018(24)00240-6
Dvora Leah Joseph Davey PhD, Rufaro Mvududu MPH, Nyiko Mashele PhD, Kalisha Bheemraj MPH, Nehaa Khadka PhD, Leigh F Johnson PhD, Sarah Schoetz Dean MPH, Prof Pamina Gorbach DrPH, Prof Linda-Gail Bekker PhD, Prof Thomas J Coates PhD, Prof Landon Myer PhD

When used effectively, oral pre-exposure prophylaxis (PrEP; tenofovir disoproxil fumarate and emtricitabine) prevents maternal HIV acquisition and reduces the risk of vertical transmission. Our study aimed to better understand PrEP initiation, continued use, and adherence in pregnant and postpartum women.

中文翻译:


南非孕妇和产后妇女开始和继续使用口服暴露前预防 (PrEP-PP):一项示范队列研究



如果使用得当,口服暴露前预防 (PrEP;富马酸替诺福韦二吡呋酯和恩曲他滨)可以防止孕产妇感染 HIV 并降低垂直传播的风险。我们的研究旨在更好地了解孕妇和产后妇女的 PrEP 开始、持续使用和依从性。
更新日期:2024-10-28
down
wechat
bug